Skip to main content

Table 1 Cataract surgery in uveitic eyes and the use of intraocular lenses: comparison of major studies in literature

From: Controversies in intraocular lens implantation in pediatric uveitis

Sources No. of patients Etiology Age at presentation of Ds in years (median) Age at Cataract surgery (years) PCIOL (in the bag) (n =eyes) Aphakia (n=eyes) Complications (n=eyes) Immunosuppression Follow-up Comments Visual outcome pseudophakia (n=eyes) Visual outcome aphakia (n=eyes)
Probst and Holland [17] (1996) 7 (8 eyes) JIA   Adults (5)
<10 (2)
PMMA   Glaucoma (4), PCO (5) Steroids 16.6 months   All >20/40  
Lundvall and Zetterstrom [28] (2000) 7 (10 eyes) JIA   3.5–10
6.5 (mean)
HSM-PMMA 10   Glaucoma (7), PCO (5), 2nd Sx for membranes (8) Steroids, methotrexate 28 months Uveitis controlled 20/20–20/50(8) <20/50(2)  
BenEzra and Cohen [15] (2000) 17 (20 eyes) JIA (8)   4–17 10 PMMA (7), diffractive (3) 7 Glaucoma (4), PS (3), CME (3) Steroids 60 months In U/L, CL poorly tolerated, JIA results guarded, uveitis active JRA
6/9–6/6(1)
6/60(1)
6/240(3)
JRA
6/9–6/6(1)
6/240(3)
Lam et al.[21] (2003) 5 (6 eyes) JIA (5) 8.5 7–12
8.5 (median)
6 PMMA (4), HSM-PMMA (1), acrylic hydrophobic (1)   PCO (6), glaucoma (2), CME (1) Methotrexate 43.5 months Uveitis controlled ALL >20/40  
Nemet et al. [16] (2007) 18 (19 eyes) JIA (10), non-JIA (9) JIA (0.9–14) Non-JIA (4.6–17) JIA (11.8+/−4.6), non-JIA (17.1+/−4.5) PMMA (7), acrylic hydrophobic (11), acrylic hydrophilic (1)   PCO (10), glaucoma (4), CME (1), 2nd Sx (11) Steroids, methotrexate,
cyclosporine
45 months No difference in visual outcome in both groups >20/40 (13)
<20/40 (6)
 
Quinones et al. [8] (2009) 34 (48 eyes) JIA (27), non-JIA (13) 6.7 (4–16) 9.8 (4–17) 13 PMMA 28 Glaucoma (3), PCO (4), RD (3), CME (4), membranes (2) Steroids, methotrexate 0.3–15.7 years
(4.1 years)
Uveitis controlled,
postsegment involved (17)
92 % improved
>20/40 (8)
20/50–20/70(4)
20/80–20/200(0)
<20/400(1)
>20/40 (9)
20/50–20/70(6)
20/80–20/200(5)
<20/400(8)
Sijssens [41] (2010) 29 (48 eyes) JIA 4.4 6.3 aphakia, 7.6 pseudophakia 29 acrylic 24, PMMA 5 19 Ocular HTN, glaucoma, CME,
optic disc involvement
Methotrexate 7 years Uveitis controlled,
aphakic surgeries till 2002, complications same in both groups
>20/40 (25)
20/40–20/200(3)
<20/200(1)
>20/40 (13)
20/40–20/200(4)
<20/200(2)
Terrada et al. [6] (2011) 16 (22 eyes) JIA (9), non-JIA (7) 5 years 9.5 (median) 22 HSM-PMMA   PCO (2), glaucoma (4), CME (3) Methotrexate, azathioprine 6.2 years Uveitis controlled 0.3 or better, log MAR  
  1. HTN hypertension, CME cystoid macular edema, RD retinal detachment, PS posterior synechiae, Sx surgery